{"entity":{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","aka":[],"tldr":"Klaus Pantel is a pioneer of circulating tumour cell research and the liquid biopsy field.","summary":"Klaus Pantel is Director of the Institute of Tumor Biology at Universitätsklinikum Hamburg-Eppendorf. His specialisms are liquid biopsy, circulating tumour cells and minimal residual disease. His work on disseminated and circulating tumour cells established liquid biopsy as a research discipline, and he coordinated the European CANCER-ID consortium. His Nature Reviews Clinical Oncology paper reviewed liquid biopsy and minimal residual disease, and their implications for cure. He is a pioneer of circulating tumour cell research, working across circulating tumour DNA and molecular residual disease testing. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pantel%20K%5BAuthor%5D%20circulating%20tumor%20cells"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["uke-hamburg"],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-reviews-clinical-oncology"],"dependsOn":[],"notes":[],"role":"Director, Institute of Tumor Biology, UKE Hamburg","institutionId":"uke-hamburg","specialisms":["Liquid biopsy","Circulating tumour cells","Minimal residual disease"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pantel%20K%5BAuthor%5D%20circulating%20tumor%20cells"}],"papers":[{"title":"Liquid biopsy and minimal residual disease: latest advances and implications for cure","journal":"Nature Reviews Clinical Oncology","year":2019,"doi":"10.1038/s41571-019-0187-3"}]},"route":"/people/klaus-pantel/","neighbours":{"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"institution":[{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"journal":[{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/"}],"idea":[{"id":"idea-fund-metastasis-moonshot","kind":"idea","name":"A ring-fenced metastasis programme with metastasis-specific endpoints","route":"/ideas/idea-fund-metastasis-moonshot/"},{"id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/"},{"id":"idea-bio2-circadian-mrd-sampling","kind":"idea","name":"Take the blood test, and give the drug, at the right time of day","route":"/ideas/idea-bio2-circadian-mrd-sampling/"},{"id":"idea-fund-ten-year-hard-problem-awards","kind":"idea","name":"Ten-year awards for scientists who commit to one hard problem","route":"/ideas/idea-fund-ten-year-hard-problem-awards/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}